Q1 EPS Estimate for Esperion Therapeutics Lowered by Analyst

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities researchers at Zacks Research lowered their Q1 2025 earnings estimates for Esperion Therapeutics in a research note issued to investors on Tuesday, March 25th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will earn ($0.19) per share for the quarter, down from their previous forecast of ($0.18). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics' Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at $0.03 EPS, FY2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.43) EPS.

ESPR has been the topic of several other research reports. Needham & Company LLC reiterated a "buy" rating and set a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, March 20th. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 target price for the company. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 price target on the stock. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Esperion Therapeutics has a consensus rating of "Hold" and a consensus price target of $6.75.

Remove Ads

Esperion Therapeutics Trading Down 3.7 %

Esperion Therapeutics stock traded down $0.06 during mid-day trading on Friday, hitting $1.45. The stock had a trading volume of 4,432,292 shares, compared to its average volume of 5,780,886. The stock has a 50-day simple moving average of $1.78 and a two-hundred day simple moving average of $2.07. The stock has a market capitalization of $285.89 million, a PE ratio of -2.26 and a beta of 1.04. Esperion Therapeutics has a 12 month low of $1.43 and a 12 month high of $3.94.

Institutional Trading of Esperion Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wasatch Advisors LP grew its position in Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company's stock valued at $38,521,000 after purchasing an additional 6,483,070 shares in the last quarter. Nuveen Asset Management LLC boosted its position in Esperion Therapeutics by 48.6% during the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock valued at $6,862,000 after purchasing an additional 1,020,243 shares during the last quarter. Bank of America Corp DE increased its position in shares of Esperion Therapeutics by 45.1% during the 4th quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company's stock worth $3,586,000 after purchasing an additional 506,428 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Esperion Therapeutics by 18.6% during the 4th quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock worth $5,399,000 after purchasing an additional 385,099 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Esperion Therapeutics in the 3rd quarter valued at approximately $606,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.